Filing Details
- Accession Number:
- 0001209191-21-058930
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-04 16:12:16
- Reporting Period:
- 2021-10-01
- Accepted Time:
- 2021-10-04 16:12:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 651311552 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1655472 | Cindy Tahl | C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131 | General Counsel And Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-10-01 | 50,000 | $6.55 | 158,048 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-10-01 | 16,312 | $58.03 | 141,736 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-01 | 21,844 | $58.96 | 119,892 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-01 | 11,844 | $59.68 | 108,048 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-10-01 | 50,000 | $0.00 | 50,000 | $6.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 116,643 | 2028-01-16 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021.
- Represents the weighted average sale price of the shares sold ranging from $57.41 to $58.36 to per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 4.
- Represents the weighted average sale price of the shares sold ranging from $58.45 to $59.44 per share.
- Represents the weighted average sale price of the shares sold ranging from $59.45 to $60.07 per share.
- This option is fully vested.
Billionaire Hedge Funds
